Search
Cytochrome b-c1 complex subunit Rieske, mitochondrial
go.drugbank.com/bio_entities/BE0003858TargetHumansThe respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … The Rieske protein is a catalytic core subunit containing a [2Fe-2S] iron-sulfur cluster.
Polypeptides: Cytochrome b-c1 complex subunit Rieske, mitochondrialSynonyms: Complex III subunit 5, Cytochrome b-c1 complex subunit 5Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.
Berotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]
Categories: Drugs Used in Hereditary AngioedemaSynonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlorideMoxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approvedIt was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class. … [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]
Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household settingRaxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigational[A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272] … It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions
Synonyms: RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptideStrontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnAvailable for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and, simultaneously, reduces the resorption of bone by osteoclasts.
Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADETProducts: RASBY 2 G ORAL SUSPANSIYON ICIN GRANUL ,100 PAKET, DIOSS 2 G EFERVESAN TABLET, 56 ADETMajor histocompatibility complex class I-related protein 1
go.drugbank.com/bio_entities/BE0003573TargetHumansIn complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1.2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers
Polypeptides: Major histocompatibility complex class I-related protein 1ATP synthase F(1) complex subunit gamma, mitochondrial
go.drugbank.com/bio_entities/BE0003842TargetHumansATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit gamma, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated
Polypeptides: ATP synthase F(1) complex subunit gamma, mitochondrialATP synthase F(0) complex subunit e, mitochondrial
go.drugbank.com/bio_entities/BE0009021TargetHumansPart of the complex F(0) domain (PubMed:37244256) … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).
Polypeptides: ATP synthase F(0) complex subunit e, mitochondrialFunction: protein-containing complex bindingStreptococcus pneumoniae type 8 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10326ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze